RTX vs VIR · P/E 36, rev $88.60B vs rev $74.2M
RTX Corporation (RTX) versus Vir Biotechnology Inc (VIR) — a side-by-side from cached financials, not a winner call.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Vir Biotechnology Inc (VIR) is a biotechnology company listed on NASDAQ.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Latest reported VIR revenue for 2024-12-31 was $74.2M. Net income was -$522.0M. Revenue was down 13.9% from 2023-12-31 to 2024-12-31. VIR currently screens at market cap $1.45B.
RTX currently screens at market cap $259.34B and trailing P/E 36.2. VIR currently screens at market cap $1.45B.
Not investment advice. Open the RTX and VIR stock pages for the full models.
Not investment advice.